Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-06-18

Next Generation HIV-1 Immunogens inducing broadly reactive Neutralising antibodies

Objective

The elicitation of broadly neutralising antibodies (Nab) remains the primary and most challenging goal in HIV-1 vaccine development. Although a few anti-HIV-1 monoclonal antibodies with broadly neutralising capability have been isolated from infected individuals, none of the immunization strategies thus far explored has proven effective in inducing similar antibodies. Objective of this application is the development of a variety of ‘next-generation’ HIV-1 envelope-based immunogens that in combination with new adjuvant formulations are capable of eliciting high-titer broadly Nab responses. Our strategy will be based on one side on the identification and cloning of envelopes that have successfully elicited broad Nabs in their natural hosts, focusing on HIV-1 strains derived from patients with high-titered broad Nabs in their sera; on the other side, we will introduce rational modifications into these and promising HIV-env based immunogens that are already under development by NGIN’s partners, with the aim of exposing cryptic conserved neutralization epitopes and permitting their efficient presentation to the immune system. HIV-1 envelopes will be expressed in viral vectors or as trimeric (gp150) soluble proteins and screened for their immunogenicity and antigenicity in rabbits. A selection of envelopes with highest antigenicity will be expressed as trimeric envelope-complexes on the surface of virosomes or virus-like particles (VLP), to further improve immunogenicity. New immunogens will be evaluated in prime-boost regimens in rabbits using novel effective adjuvant formulations. Immunogen/adjuvant combinations that prove most effective in eliciting broadly Nabs both systemically and at the mucosal level will be evaluated in non-human primates for their immunogenicity and efficacy upon challenge with live heterologous virus. Finally, formulations that will elicit protective immunity in non-human primates will be forwarded for proof-of-principle testing in humans.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

FP7-HEALTH-2007-A
See other projects for this call

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

CP-IP - Large-scale integrating project

Coordinator

UNIVERSITA VITA-SALUTE SAN RAFFAELE
EU contribution
€ 76 476,57
Address
VIA OLGETTINA 58
20132 Milano
Italy

See on map

Region
Nord-Ovest Lombardia Milano
Activity type
Higher or Secondary Education Establishments
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Participants (17)

My booklet 0 0